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Bone marrow cells contribute to regeneration of damaged
glomerular endothelial cells.
Background. There is accumulating evidence that adult bone
marrow (BM) cells show unexpected plasticity, and can differen-
tiate into a wide range of specialized cells. In the case of intrinsic
renal glomerular cells, BM-derived cells have been reported to
differentiate into both mesangial cells and podocytes. However,
there is controversy on recruitment of glomerular endothelial
cells, although endothelial cells in other tissues are known to be
recruited from the BM.
Methods. Sprague-Dawley (SD) rats and SD rats made
chimeric by transplantation of bone marrow cells from en-
hanced green fluorescent protein (EGFP) transgenic littermate
rats, were injected with anti-Thy-1.1 antibody, followed by uni-
lateral nephrectomy (1-kidney model). Chimeric rats used in
1-kidney model were sacrificed for histologic examination at
weeks 2, 4, 8, and 11. We examined isolated glomeruli and frozen
sections of kidneys from rats of each group at weeks 2 and 11
by confocal laser scan microsopy (CLSM), both immunohisto-
logically and three dimensionally.
Results. In the 1-kidney group, using chimeric rats trans-
planted with EGFP(+) bone marrow cells, most rats died,
presumably of uremia, after 8 to 11 weeks. A CLSM study
using isolated glomeruli and frozen sections of kidneys re-
vealed that bone marrow-derived PECAM-1(+), RECA-1(+)
cells, and OX-7(+) cells contributed to the structural sup-
port for the glomerular capillaries during the chronic course.
Global glomerular sclerotic lesions and diffuse tubular atrophic
changes, with interstitial cell infiltration, were remarkable at
weeks 8 and 11.
Conclusion. Bone marrow–derived endothelial progenitor
cells participated in glomerular endothelial cell turnover af-
ter severe damage. Treatment that could target bone marrow–
derived endothelial progenitor cells and promote angiogenesis
in regions of progressive glomerular lesions may be a promising
therapeutic approach for preventing end-stage renal disease.
Key words: bone marrow–derived endothelial progenitor cells, recon-
stitution of glomerular endothelial cells, EGFP-transgenic rats, pro-
gressive glomerulosclerosis.
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The circulatory system is indispensable for maintain-
ing homeostasis of the interior milieu by supplying the
body tissues with blood in doses proportionate to their re-
quirements for oxygen and nutrients, and for removal of
waste products, including carbon dioxide, for excretion by
the kidneys and lungs. Microvascular endothelial cells are
known to play active roles in preserving the fundamen-
tal structure of tissues and controlling blood flow. There-
fore, endothelial cell turnover and recruitment have been
the focus of research in many physiopathologic condi-
tions. There is growing evidence that adult bone marrow
cells show unexpected plasticity, and can differentiate
into a wide range of specialized cells, such as hepato-
cytes [1], skeletal muscle cells [2], cardiomyocytes [3],
and neuronal cells [4]. In the case of renal glomerular
cell components, bone marrow (BM)-derived cells have
been reported to differentiate into both mesangial cells
(MCs) and podocytes [5]. However, there is controversy
concerning recruitment of glomerular endothelial cells
(GECs) [6–8], although it is well known that endothelial
cells in other tissues are recruited from BM [9].
In a recent study [10], we presented a useful experimen-
tal model for analyzing the pathogenesis of progressive
glomerulosclerosis caused by unilateral nephrectomy
following MC injury (1-kidney model). In comparison
with reversible 2-kidney model (conventional anti-Thy-1
model), regeneration of glomerular endothelial cells was
remarkably suppressed, leading to irreversible glmeru-
losclerosis with renal insufficiency. An important obser-
vation was the positive association between impairment
of vascular regeneration and development of progressive
glomerulosclerosis, suggesting that angiogenesis and vas-
cular remodeling in the 1-kidney model may be different
from those in the 2-kidney reversible model.
Here, we report that BM-derived endothelial progen-
itor cells (EPCs) play a pivotal role in the recruitment of
GECs in progressive 1-kidney model of anti-Thy1 anti-
body nephritis induced in chimeric rats transplanted with
green fluorescent protein (GFP)-positive BM cells.
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METHODS
Animals
Transgenic Sprague-Dawley (SD) rats carrying the
enhanced green fluorescent protein (EGFP) transgene
(EGFP rat) were purchased from Japan SLC, Inc.
(Hamamatsu, Japan; by permission of Dr. M. Okabe, Os-
aka University), and were maintained and cross-mated to
obtain littermates of GFP-positive and -negative (wild-
type) rats. Rats were kept at the animal facility of
Niigata University School of Medicine; they were allowed
free access to standard laboratory diet and tap water.
The EGFP rats were originally established by use of the
same construct and technique described for production of
EGFP transgenic mice [11]. The expression of EGFP was
under the control of the cytomegalovirus enhancer and
the chicken beta-actin promoter that were derived from
an expression vector, pCAGGS. All experimental proto-
cols were approved by the animal committee of Niigata
University.
Bone marrow transplantation (BMT)
When rats were 5 weeks old, BMTs were performed
by use of SD rats (wild-type, EGFP−) as recipients, and
their siblings (EGFP+) as donors. EGFP-positive rat BM
was collected by flushing bone shafts of femurs, tibiae,
and humeri of EGFP rats with phosphate-buffered saline
(PBS). After sieving through 75-lm and 50-lm meshes,
the cells were resuspended at a concentration of 1 to
2×108 cells/mL and kept on ice until use. Littermate
rats of wild-type, EGFP(−) were lethally irradiated (10
Gy per animal with an x-ray generator (PS-3000 SB Cs-
137; Pony Industry Co., Ltd., Osaka, Japan), and within
4 hours after irradiation, BM cells were administered via
the tail vein. The chimeric rats (wild-type rats that had
received EGFP+ BMT) were not treated with any drugs
after BMT.
The nephritogenic antibody (Ab): 1–22-3 Ab
1–22-3 Ab, the nephritogenic anti-Thy 1 monoclonal
antibody, was prepared as described previously [12]. The
nephritogenicity of the 1–22-3 Ab appeared to be higher
than that of the commercially available anti-Thy 1.1 Ab,
OX-7 [13].
Experimental protocol
First, we checked the nephritogenicity of 1–22-3 Ab
and rat strain differences in susceptibility to nephritis
induced in the 2-kidney model (sham operation group)
and 1-kidney model (uninephrectomized group), using
SD rats of wild type. These rats were injected with 1–22-
3 Ab, and sacrificed at week 12 after injection. Second,
male rats of wild type were given BMT from their EGFP-
positive brothers at 5 weeks of age. These chimeric rats
were divided into the 2 groups. In the 1-kidney model,
chimeric rats were injected intravenously with 0.5 mg of
1–22-3 Ab and uninephrecomized 30 minutes thereafter.
Four chimeric rats were sacrificed at weeks 2, 4, and 8, and
3 chimeric rats were sacrificed at 11 week after the injec-
tion of 1–22-3 Ab. As a control, 3 chimeric rats, without
injection of 1–22-3 Ab, were sacrificed at week 17 after
BMT.
Biochemical analysis of serum
At sacrifice, blood was collected from all chimeric rats
used, and total serum protein (TP), serum albumin (Alb),
creatinine (Cre), and blood urea nitrogen (BUN) were
measured.
Urinary analysis
Chimeric rats with and without anti-Thy1 nephritis
were individually housed in metabolic cages, with free
access to water, for collection of 24-hour urine specimens
on day 3, and weeks 1, 2, 4, 8, and 11 after the injection
of 1–22-3 Ab. The amount of urinary protein excreted
was determined by the biuret method with bovine serum
albumin (BSA) as a standard.
Light microscopy
Tissue for light microscopy was fixed in 10% neutral-
buffered formalin. Paraffin sections were cut at 4-lm and
stained with hematoxylin-eosin (HE). In addition, kidney
sections were stained with periodic acid–Schiff (PAS) and
periodic acid methenamine silver (PAM), sections from
liver and lung were stained with Azan.
Examination of cell markers on frozen sections and in
isolated glomeruli by immunofluorescence
Indirect immunofluorescence was performed on 4-
lm frozen sections followed by fixation with cold ace-
tone. Isolated glomeruli from rat kidneys were pre-
pared by a mechanical sieving method, as described
previously [14]. Isolated glomeruli were fixed with 2%
paraformaldehyde for 2 hours, and washed with PBS
and treated with 1 mg/mL collagenase-dispase for 15
minutes at room temperature, followed by 0.04% Tri-
ton X 100 for 5 minutes. Glomeruli were then stained
with the primary antibody at 4◦ overnight, and washed
with PBS. Incubation with the second antibody was for
1 hour at room temperature and stained with the pri-
mary antibodies, OX-7, anti-rat Thy1 mouse Ab (a hy-
bridoma producing OX-7 IgG1 was purchased from Eu-
ropean Collection of Animal Cells Porton Down, Sal-
isbury, UK) for identifying glomerular MC, and antirat
PECAM-1, and antirat RECA-1 mouse Abs (Serotec,
Ltd., Kindlington, UK) for identifying glomerular en-
dothelial cells (GECs). Rabbit anti-von Willebrand’s fac-
tor (vWF) antibody (Dako, Glostrup, Denmark) was used
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Fig. 1. Urinary protein excretion in the 1- and 2-kidney models of wild
SD rats. Urinary protein excretion was determined in 24-hour urine
specimens at the indicated times after injection of 1–22-3 Ab. Data are
expressed as mean values ± SD. ∗P < 0.05 vs. 2-kidney group.
as a functional marker of vascular endothelial cells [12].
Rabbit antirat laminin antibody (Sigmal Chemical Co.,
St. Louis, MO, USA) was used as a staining marker of
basement membrane. The secondary Ab was tetramethyl
rhodamine B isothiocyanate (TRITC)-conjugated anti-
mouse and -rabbit immunoglobulins (Igs) Ab (Dako). Of
note, 3-time washings with PBS after antibody incubation
were limited to 5 minutes duration, due to the high water-
solubility of EGFP. For conventional immunofluorescece
of the sections and 3-dimensional analysis of isolated
glomeruli, we used confocal laser scanning immunoflu-
orescent microscopy (CLSM) with the MRC-1024 con-
focal imaging system (Bio-Rad Laboratories, Hemel
Hempstead, UK) [15].
Statistics
Data are expressed as mean ± SD. Statistical signifi-
cance was evaluated by the Student t test or nonparamet-
ric Mann-Whitney U test. A value of P < 0.05 was taken
to denote statistical significance.
RESULTS
The reversible 2-kidney and irreversible 1-kidney models
in SD rats
To confirm the nephritogenicity of monoclonal Ab
1–22-3 and rat strain difference in susceptibility to
nephritis, as described previously [10], in the 2-kidney
model (sham operation group) and 1-kidney model
(uninephrectomized group) using SD rats of wild type,
urinary protein excretion was determined for 12 weeks
(Fig. 1). There was a significant difference in the results
of urinary analysis from 4 weeks onwards, after disease in-
duction, between 1- and 2-kidney models. In the 1-kidney
group, urinary protein excretion was 40.2 ± 10.0 mg/24h
at 4 weeks, and increased with time to 104.5 ± 37.2 mg/24h
at 12 weeks, while urinary protein excretion decreased
to normal levels in the 2-kidney model with time. Serum
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Fig. 2. Bone marrow reconstitution by bone marrow transplantation
from EGFP-positive donors. Smear specimens of bone marrow cells
from EGFP(−) recipients after bone marrow transplantation from
EGFP(+) donors were examined with fluorescent microscopy. The per-
centage of donor EGFP-positive cells in the recipient’s bone marrow af-
ter bone marrow transplantation were calculated at the indicated times.
The shaded zone shows the range (average ± SD) of GFP(+) bone mar-
row cells from 3 EGFP-transgenic rats. The closed circles showed the
averages of EGFP(+) cells in the recipients’ chimeric bone marrow
after bone marrow transplantation.
creatinine values were significantly higher in the 1-kidney
group than in the 2-kidney group at week 12 after injec-
tion of 1–22-3 Ab, 0.49 ± 0.03 and 0.35 ± 0.04 mg/dL, re-
spectively [(P < 0.05) (0.38 ± 0.05 mg/dL in age-matched,
control rats (N = 5)].
General features of 1-kidney model in chimeric rats trans-
planted with EGFP-positive BM cells
We confirmed the nephritogenicity of monoclonal Ab
1–22-3 in SD rats made transgenic to carry the EGFP
(EGFP rat). Then, BMT studies using SD rat were done to
examine whether bone marrow–derived progenitor cells
are involved in recruitment of cellular components to
glomeruli after severe damage, resulting in progressive
glomerulosclerosis in 1-kidney model. To avoid as far as
possible interfering phenomenon, such as a graft-versus-
host reaction, in chimeric rats, BM cells obtained from
sibling EGFP-positive rats were transplanted to their lit-
termate rats.
To examine BM reconstitution by BMT from EGFP-
positive donors, and to determine the time-point for in-
duction of glomerular injury, the recipient’s BM was ex-
amined by fluorescent microscopy 1 to 7 weeks after
BMT. The ratio of donor EGFP positive to negative BM
cells in the recipient’s BM increased with time, and, at
5 weeks, reached the normal ratio of EGFP-positive to -
negative cells seen in EGFP transgenic rats without treat-
ment (Fig. 2). Therefore, a time-point of 5 weeks after
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Table 1. Laboratory data after disease induction (1-kidney model) in
chimeric rats transplanted with EGFP(+) bone marrow cells
Urinary
protein
excretion Serum TP BUN Creatinine
mg/day g/dL mg/dL mg/dL
2 week (N = 4) 59.8 ± 30.5a 6.2 ± 0.4 55.3 ± 4.7a 0.52 ± 0.15
8 week (N = 4) 42.9 ± 9.9a 4.7 ± 0.4a 257.5 ± 57.0a 2.59 ± 0.85a
11 week (N = 3) 230.0 ± 50.1a 4.5 ± 0.5a 320.4 ± 70.5a 3.81 ± 0.91a
Control (N = 3) 8.5 ± 5.0 5.7 ± 0.4 34.2 ± 7.8 0.44 ± 0.06
Each value is expressed as mean ± SD. Five of 8 chimeric rats in the 1-kidney
model died presumably of renal insufficiency during the period 8 to 11 weeks
after disease induction. The surviving 3 rats were sacrificed for examination at
11 weeks after disease induction. Control: bone marrow chimeric rats, 17 weeks
after bone marrow transplantation, without anti-Thy-1 antibody injection.
aP < 0.01 vs. control.
BMT was selected for induction of glomerular injury.
Three rats of wild type that were irradiated without trans-
plantation of EGFP-positive BM cells died on days 4, 8,
and 9, respectively, after total body irradiation (TBI). On
the contrary, rats of wild type that received BMT from
EGFP-positive littermates following TBI were still alive
5 months thereafter, without any apparent histopatho-
logic findings at sacrifice (data not shown).
Urinary protein excretion and serum biochemical data
after 1–22-3 Ab injection in the control, and 1-kidney
chimeric groups is shown in Table 1. Proteinuria and
serum levels of creatinine in control chimeric rats ap-
peared to be normal. In the 1-kidney group, serum BUN
and creatinine values were significantly higher than those
in the 2-kidney group at 8 weeks, reaching levels indi-
cating chronic renal insufficiency (Table 1). Rats in the
1-kidney group were severely ill and malnourished, as
reflected by reduced levels of total serum proteins, re-
stricting levels of proteinuria. Impressively, 5 of 8 rats in
the 1-kidney group died between 8 and 10 weeks, showing
generalized emaciation, presumably due to uremia.
Histologically, no pathologic findings were observed in
the control chimeric rats at 17 weeks after BMT (Fig. 3A).
At week 2 after injection of 1–22-3 Ab, there were mesan-
gioproliferative, and persistent mesangiolytic lesions with
mild sclerosis in the 1-kidney group (Fig. 3B). At week 4,
severe mesangial matrix expansion with glomerular scle-
rotic lesions was often observed in the 1-kidney group
(data not shown). As shown in Figure 3C, in the 1-kidney
group at week 8, glomerular sclerotic lesions and diffuse
tubular atrophic changes with interstitial cell infiltration
were much more dominant. At week 11 when examined
finally, globally sclerotic glomeruli and remarkable inter-
stitial cell infiltration and fibrosis were found diffusely
(Fig. 3D).
Identification of EGFP-positive cells recruited within
glomeruli
In the present work, we have focused on the role of BM-
derived, nonhematopoietic progenitor cells in the regen-
Fig. 3. Light microscopic findings in the kidney in the 1-kidney model
using chimeric SD rats transplanted with EGFP(+) bone marrow cells.
There were no pathologic findings in the control chimeric rat at 17
weeks after bone marrow trasplantation (A). At week 2 after injec-
tion of 1–22-3 Ab, diffuse mesangial cell proliferation and mesangial
matrix expansion was found. Persistent mesangiolytic lesions were also
found (B). At week 8 after Ab injection, severe mesangial matrix ex-
pansion with severe sclerotic lesions was observed in the majority of
the glomeruli. Exudation into the Bowmann’s space and urinary casts
were also found (C). Global glomerular sclerosis and diffuse tubular
atrophic changes with interstitial cell infiltration and fibrosis became
much more prominent at week 11 (PAS stain).
eration of resident glomerular cells after severe glomeru-
lar damage, leading to progressive glomerulosclerosis.
Two weeks after administration of 1–22-3 Ab in
chimeric rats, we examined the recruitment of bone
marrow–derived cells into the glomeruli in the 1-kidney
group by immunofluorescence with cell-specific markers.
Figure 4 shows intraglomerular cells expressing EGFP
and either OX-7 as a mesangial cell marker, or PECAM-
1 and RECA-1 as endothelilal cell markers. Distorted
staining patterns of mesangial cells and loss of capillary
densities indicated that mesangial cell injury, followed by
destructive changes of glomerular capillaries, persisted.
By computer-aided superimposition of the 2 fluorescence
images, colocalization of EGFP and OX-7 or EGFP and
PECAM-1 or RECA-1 generated a yellow fluorescence.
There were many EGFP(+) cells, some of which were
costained with OX-7 (Fig.4C) and PECAM-1 (Fig. 4F) in
the 1-kidney group. Other numerous EGFP(+) cells and
particle-like cell components without costaining for OX-7
or PECAM-1 seemed to be bone marrow–derived inflam-
matory cells, such as polymorphonuclear leukocytes and
monocytes, and platelets, as the acute phase of inflamma-
tion still persisted 2 weeks after disease induction.
Light microscopic findings in the present study showed
that progressive glomerulosclerotic lesions, associated
with renal insufficiency, occurred in the 1-kidney model,
as described previously [10]. To investigate microvas-
cular regeneration and formation of glomerulosclerotic
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Fig. 4. Recruitment of EGFP (+) bone mar-
row cells into the glomeruli at 2 weeks after the
injection of 1–22-3 Ab, in the 1-kidney model.
Isolated glomeruli were incubated with mon-
oclonal antibody to OX-7 as a mesangial
cell maker (A) or monoclonal antibody to
PECAM-1 (D), as an endothelial cell marker,
followed by staining with TRITC-conjugated
anti-mouse Igs Ab (red color). By computer-
aided superimposition of the two fluorescence
images, EGFP(+) cellular colocalization of
OX-7 (C) or PECAM-1 (F), generated a yel-
low fluorescence (arrows). There are many
EGFP(+) cells that were costained with OX-
7 or PECAM-1 in the 1-kidney group (C, D).
Of note, other numerous EGFP(+) cells and
particle-like cell components without mesan-
gial or endothelial cell-markers were found.
The scales were indicated by lm.
lesions, glomeruli isolated from a chimeric rat in the 1-
kidney group that survived, despite renal insufficiency,
were examined at week 11 after injection of 1–22-3 an-
tibody. The density of glomerular capillaries evaluated
by anti-PECAM-1 or anti-RECA-1 staining decreased
remarkably in the 1-kidney group compared to that
of normal control groups (Fig. 5). Furthermore, cellu-
lar colocalization of EGFP(+), PECAM-1 (Fig. 5C), or
RECA-1 (Fig. 5D) suggested strongly that bone marrow–
derived EPCs were incorporated into the damaged
capillary beds. CLSM, in combination with immunostain-
ing and optical sectioning of isolated glomeruli, allowed
3-dimensional analysis and characterization of EGFP-
positive BM-derived cells within glomeruli. Sequential
images of glomerular capillary tufts (2 lm in thickness)
showed EGFP(+) cells in a mosaic pattern mingled
with endothelial cells indicated by PECAM-1 staining,
as shown in Figure 6.
To examine more precisely the recruitment of bone
marrow–derived EPCs into the severely damaged
glomerular vasculatures, frozen kidney sections fixed
with acetone were used for immunostaining, although
detectablity for EGFP-positive cells was relatively low,
probably due to the high water solubility of EGFP. Some
glomerular endothelial cells immunostained with anti-
PECAM-1 or RECA-1 antibody were colocalized with
EGFP, showing the involvement of bone marrow–derived
EPCs in the regeneration of glomerular microvascula-
ture (Fig. 7). At the same time, there were very few
EGFP(+) cells costained with the mesangial cell marker
OX-7 (Fig. 8). In terms of endothelial function after re-
cruitment of bone marrow–derived endothelial precursor
cells, we examined the production of von Willebrand’s
factor (vWF) in glomerular endothelial cells using im-
munofluorescence. Figure 9 showed colocalization and
proximal localization of vWF with EGFP-positive cells
within glomeruli, suggesting that glomerular endothelial
cells recruited from bone marrow exhibited endothelial
specific functions.
During the time course examined, we never found ab-
normal depositions of autologous immunoglobulins and
C3 in the glomeruli in any experimental group (data not
shown).
DISCUSSION
Regeneration of the microvasculature after injury is
indispensable for maintaining tissue- and organ-specific
structures and functions. Recent studies have revealed
that glomerular capillary repair is the key to determin-
ing the progression of glomerular pathology. In models
of glomerulonephritis exhibiting recovery from injury,
such as anti-Thy-1 glomerulonephritis and Habu snake
venom–induced glomerular injury, vascular remodeling
is an essential step leading to full recovery of glomeru-
lar architecture [16, 17]. In addition, there is increasing
evidence that impaired angiogenesis may occur in the dis-
eased kidney, resulting in irreversible renal sclerosis [10,
18, 19].
It is now established that BM-derived EPCs can dif-
ferentiate into endothelial cells that contribute to angio-
genesis or vasculogenesis in postnatal neovascularization
[9, 20–22]. There have been no published data showing
that loss of glomerular endothelial cells (GECs) due to
injury is followed by recruitment of BM-derived EPCs, al-
though the BM has been reported to serve as a reservoir
for MCs [6, 7]. Very recently, Rookmaaker et al, using
a rat allogenic BM transplant model, reported that bone
marrow–derived endothelilal cells could be recruited and
integrated into the glomerular structure in anti-Thy1-
glomerulonephritis [8]. These latter authors showed that
donor-derived EPCS could be detected with a specific
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Fig. 5. Recruitment of EGFP(+) bone marrow cells into the glomeruli
11 weeks after the injection of 1–22-3 Ab in the 1-kidney model. Isolated
glomeruli were incubated with monoclonal antibodies to PECAM-1
(A) or RECA-1 (D), followed by staining with TRITC-conjugated an-
timouse Igs Ab. Microvascular structures composed of cellular colocal-
ization of EGFP(+) and PECAM-1 were found in contact with non-
vascular lesions, presumably sclerotic lesions (C, arrows). The same
colocalization of RECA-1 used for the other endothelial marker was
also observed (D).
monoclonal antibody that is able to recognize the dif-
ference in histocompatiblity antigens between donor and
recipient MHCI. There is discrepancy between published
results, using a similar model of reversible anti-Thy-1
glomerulonephritis, between Rookmaaker’s and another
paper of Ito et al [7], in which bone marrow–derived cells
replaced a part of mesangial cells, but not endothelial
cells in the glomerulus.
Here, we showed that BM-derived EPCs can differ-
entiate into GECs as well as MCs during the chronic
phase of irreversible, anti-Thy 1 Ab-mediated glomeru-
lonephritis. Before going into a discussion of the signifi-
cance of recruitment of BM-derived EPCs after damage,
we wish to consider reasons for the differences between
our present data and between previous papers concern-
ing involvement of bone marrow–derived EPCs. First, in
our present study, we analyzed the contribution of EPC
in the model of progressive glomerulosclerosis induced
by a 1-shot injection of anti-Thy 1 antibody followed by
unilateral nephrectomy (1-kidney model) [10] using SD
rats with transplanted, GFP-positive BM cells. In compar-
ison with reversible anti-Thy-1 model (2-kidney model),
glomerular microvasculatures suffered from more severe
injury, and showed disturbed regeneration after disease
induction, as described previously [10]. There is increas-
ing evidence that bone marrow stem cell “plasticity” is not
a normal function of EPCs, but that the EPCs are likely
to be incorporated into the lesions of severe injury un-
der selective pressure, due to their atypical function [23,
24]. In Rookmaaker’s work [8], as described above, allo-
geneic bone marrow transplantation from WAG/RijHsd
to Brown Norway/RijHsd may affect the function of
EPCs or the degree of injury induced in the glomeru-
lar microvasculature. Second, isolated glomeruli fixed im-
mediately with 2% paraformaldehyde or frozen sections
fixed with acetone followed by short-time washings were
used for detection and analysis of EGFP-positive cells, in
contrast to the study by Ito et al, who performed immuno-
histologic studies using thin frozen sections from the kid-
neys previously perfused, and fixed with 10% buffered
formalin via the abdominal aorta [7]. The isolation pro-
cedure for glomeruli, in combination with analysis using
CLSM, causes little mechanical injury to intraglomerular
cells, as shown previously [15]. Tissue sectioning, followed
by extensive washing during immunostaining, may result
in loss of GFP from fragile endothelial cells, even after
fixation, because GFP is very water soluble and easily
diffuses through damaged cell membranes. Third, there
are differences in the nephritogenicities of the anti-Thy-1
antibodies used for induction of glomerulonephritis. Ito
et al used OX-7, a commercially available MAb of IgG1
subclass, and Rookmaaker et.al used ER4, Mab of IgG2a
[25], while we used another monoclonal Ab, called 1–22-3
(IgG3 subclass), which we produced, and which appeared
to be more nephritogenic than OX-7 [13].
Recently, it has been highlighted that bone marrow
cells have the capacity to fuse with embryonic stem cells
and differentiate in vitro [26]. In addition, Wang et al
have shown that regenerated hepatocytes, in a mouse
model of tyrosinemia, could arise from the stable fu-
sion of bone marrow–derived cells with host hepato-
cytes [27]. Analyzing these data, cell fusion appears to
be a very low-frequency event, occurring at the level of
once in 104 to 105 cells [24]. On the other hand, Bailey
et al have excluded the possibility of cell fusion as the
principal mechanism responsible for the generation of
functional endothelial cells from stem cells in the mouse
portal vein endothelium [28]. Very recently, using the so-
phisticated method of the Cre/lox recombinase system,
in combination with b-galactosidase and EGFP expres-
sion, it was demonstrated that epithelial cells in the lung,
liver, and skin developed from bone marrow–derived
stem cells without cell fusion [29]. Although we cannot
exclude the possibility that cell fusion of bone marrow–
derived cells with intrinsic microvascular endothelial cells
of recipient origin may occur, it is reasonable to consider
that bone marrow–derived EPCs can repair the damaged
glomerular capillaries without cell fusion in the 1-kidney
model of anti-Thy-1 glomerulonephritis. This is because
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Fig. 6. Sequential images of an isolated
glomerulus (2 lm in thickness), obtained by
optical sectioning of the same area shown in
Figure 5 (indicated by the white-line square),
revealed that some glomerular capillary tufts
were composed of EGFP(+) cells in a mosaic
pattern, as indicated by PECAM-1 staining
(arrows).
Fig. 7. EGFP(+) cellular colocalization of
endothelial cell markers in frozen kidney sec-
tions 11 weeks after the injection of 1–22-3 Ab
in the 1-kidney model. Frozen specimens fixed
with acetone were incubated with monoclonal
antibodies to RECA-1 (A) or PECAM-1 (D),
followed by staining with TRITC-conjugated
antimouse Igs Ab. EGFP(+) cellular colo-
calization of RECA-1 (C) or PECAM-1 (F)
was found within a glomerulus (arrows). The
scales were indicated by lm.
Fig. 8. EGFP(+) cells localized in the in-
terstitium and EGFP(+) cellular colocaliza-
tion of mesangial cell marker, OX-7. Frozen
specimens fixed with acetone were incubated
with monoclonal antibody OX-7, followed by
staining with TRITC-conjugated antimouse
Igs (A). EGFP(+) cellular colocalization of
OX-7 was rarely found within glomeruli (ar-
rows). With the aid of basement membrane
staining by rabbit antilaminin antibody, fol-
lowed by staining with TRITC-conjugated an-
tirabbit Igs, many EGFP(+) cells were found
in the interstitium (arrow heads), as described
by Ito et al [7]. The scale was indicated by lm.
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Fig. 9. EGFP(+) cellular colocalization of a specific, functional
marker of endothelial cell. Frozen specimens fixed with acetone were
incubated with monoclonal antibodies, RECA-1 (A) or rabbit anti-
vWF (D) antibody, followed by staining with TRITC-conjugated an-
timouse Igs or antirabbit Igs, respectively. GFP(+) cellular colocaliza-
tion of RECA-1 (C) was found. In addition, colocalization (arrow) and
proximate localization (arrow heads) of vWF with GFP(+) cells were
observed (D). The scale was indicated by lm.
of the higher frequency of recruitment of GFP(+) bone
marrow–derived cells with specific endothelial markers
and exhibiting endothelial specific functions, such as ex-
pression of PECAM-1, cell adhesion molecule, and pro-
duction of vWF. It is well known that cell fusion of
normal somatic cells yields multinuclear cells of specific
fusion, resulting in loss of cell function, such as prolifer-
ation [24]. Alvarez-Dolado et al reported that the hepa-
tocytes and cardiomyocytes that have undergone fusion
down-regulate the expression of GFP, and thus, could
possibly inactivate the donor genes overtime [30]. Fur-
ther study is needed in our experimental model to pro-
vide the direct evidences that GFP(+) vasculature is not
due to the cell fusion.
It is worthwhile discussing the pathomechanisms
involved in inducing revascularization in glomerular in-
jury from the angle of chronic ischemia. Our compar-
ative study in the 1- and 2-kidney models showed that
there was a positive association between impairment of
vascular regeneration and the development of glomeru-
losclerosis [10]. Loss of capillary density and blood flow
may result in poor delivery of oxygen and nutrients
to the damaged area, producing chronic ischemia [19].
There was a dramatic decrease of capillary density by
day 3 after disease induction in the acute phase of the
ATS model [10]. Semiquantitative analysis by reverse
transcription-polymerase chain reaction (RT-PCR) indi-
cated that mRNA expression of PECAM-1 and VEGF
was significantly suppressed by day 14 in the 1-kidney
group compared to the 2-kidney group. Asahara et al re-
ported extensive studies on the contribution of VEGF
to postnatal neovascularization in ischemia and/or reper-
fusion injury [31–33]. They showed evidence that VEGF
may modulate both differentiation of EPC in vitro, as well
as the kinetics of mobilization from BM in vivo, suggest-
ing that VEGF has multipotential roles in endothelial cell
growth, cell differentiation, and chemoattractive mobi-
lization of BM mononuclear cells, including EPC. The in-
trinsic cellular source of VEGF is the glomerular visceral
epithelial cells [34]. In a physiologic setting, hydrostatic
pressure across glomerular capillary walls prevents fluid,
containing biologically active substances such as VEGF
and hepatocyte growth factor from flowing back from
the Bowman’s space to the endocapillary region. Inter-
estingly, real-time observation of glomerular blood flow
in the ATS model revealed that there was hemostasis
within microaneurysms at day 3. The blood flow within
glomeruli was retarded with less injury; the level of blood
flow was about one tenth of that seen in normal control
subjects [35]. In such a pathologic setting, the occurrence
of hemostasis as seen at day 3 in the ATS model, VEGF
produced by glomerular visceral epithelial cells may ex-
hibit biological activity on the damaged endocapillary
lesions, resulting in neovascularization by both vascular
sprouting from the remaining vessels and/or by recruit-
ment of EPCs from BM.
CONCLUSION
In remodeling of glomerular structures after damage,
the revascularization process is a key factor in determin-
ing prognosis of glomerular injury, as described above.
From a therapeutic viewpoint, future studies on deliver-
ing bone marrow–derived endothelial EPCs, or passive
administration of bone marrow–derived EPCs and sub-
sequent activation of angiogenesis and/or vasculogene-
sis by transfer of angiogenetic factors such as VEGF,
HGF, and the relevant genes will be needed to halt,
or promote recovery from irreversible progression to
glomerulosclerosis.
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